Home Ingredients Bemethyl (Bemitil / Metaprot)
EnergyAthletic PerformanceCognitive

Bemethyl (Bemitil / Metaprot)

Synthetic — benzimidazole actoprotector
Evidence Level
Limited
3 Clinical Trials
6 Documented Benefits
2/5 Evidence Score

Synthetic benzimidazole 'actoprotector' developed in the 1970s by Vladimir Vinogradov at the S.M. Kirov Military Medical Academy (Leningrad, USSR). Original prototype actoprotector — class definition: enhances physical and mental performance under stress without increasing oxygen consumption (distinguishing from typical stimulants). First given to Soviet cosmonauts and the USSR national athletic team for the 1980 Moscow Olympic Games. Later used by Soviet/Russian armies including the Afghanistan war for soldier performance under hypoxia, hot weather, and prolonged marches. Approved for medicinal drug status in Ukraine, Moldova, and Georgia; available as Antihot dietary supplement in Ukraine. WADA monitoring program 2018 — flagged for documented ergogenic effects. Not FDA-approved.

Studied Dose Russian/CIS approved: 250-500 mg 1-2x/day for asthenia; courses 3-5 days with 2-3 day breaks. Athletic: 250 mg 2x/day.
Active Compound Bemethyl (2-(ethylsulfanyl)-1H-benzimidazole hydrobromide; bemitil, metaprot, bemiton, bemactor, antihot, ethylthiobenzimidazole) - synthetic benzimidazole derivative.

Benefits

Asthenic disorders (1988 RCT vs piracetam/pyriditol)

An asthenic disorders RCT showed bemethyl superiority vs piracetam and pyriditol - 78% improvement at day 10. Russian-language methodology limits Western evidence assessment, but the head-to-head design against active comparators is methodologically meaningful.

Supported by Trial 1

Physical performance enhancement (Soviet cosmonauts/athletes)

Documented historical use: Soviet cosmonauts (space program), USSR national athletic team for 1980 Moscow Olympic Games, and Soviet/Russian military personnel. Real-world ergogenic application across high-stress, high-demand contexts — supports the actoprotector class definition.

Supported by Trial 2, Trial 3

Hypoxia tolerance and altitude performance

Antihypoxant mechanism — reduces oxygen requirements under stress. Used in Afghanistan war for soldier performance under high-altitude hypoxia and hot weather. Distinguishing from oxygen-consuming stimulants.

Supported by Trial 2

Heat tolerance and combined CO/heat protection

Combined carbon monoxide and heat resistance enhancement. Occupational stress resistance evidence; relevant to firefighting, military, and industrial exposure contexts.

Supported by Trial 2

Liver regeneration support (Gaĭvoronskaia)

Documented liver regeneration support - preclinical evidence for hepatic-recovery applications. Mechanism complement to the broader stress-protective profile.

Supported by Trial 1, Trial 2

Cognitive performance under stress

Preclinical and clinical evidence for cognitive performance enhancement under stress conditions. Distinguishes from purely physical performance — supports the dual physical/mental positioning of the actoprotector class.

Supported by Trial 2, Trial 1

Mechanism of action

1

Mitochondrial protein synthesis enhancement

Bemethyl enhances mitochondrial protein synthesis — supports increased cellular energy capacity under stress. Mechanism distinct from mitochondrial uncoupling or stimulant adrenergic pathways.

2

Antihypoxant — reduced oxygen requirements under stress

Reduces cellular oxygen requirements during stress states. The class-defining actoprotector mechanism — enables performance enhancement without increased oxygen consumption.

3

Antioxidant activity

Antioxidant activity protects tissues from stress-induced oxidative damage — complements the antihypoxant effect.

4

Cumulative tissue accumulation

Resists metabolization and accumulates in tissues (1.38× brain, 1.68× liver in rats over treatment course). Long-lasting effects beyond dosage discontinuation — explains the course-based dosing pattern (3-5 days on, 2-3 days break) used in Russian protocols.

5

Antimutagenic effects

Documented antimutagenic activity — supports the broader stress-protective and tissue-recovery profile beyond pure performance enhancement.

6

Enhancement of other CNS drugs

Enhances effects of nootropic, stimulant, and adaptogen compounds while reducing side effects of antibiotics, immunosuppressants, and tranquilizers. Pharmacological adjuvant profile — relevant to stack contexts.

Clinical trials

1
Asthenic Disorders Clinical Trial (Bemethyl vs Piracetam vs Pyriditol)

1988 head-to-head clinical trial in asthenic disorders.

Clinical population described in trial publication.

1988 head-to-head clinical trial in asthenic disorders. Bemethyl showed 78% improvement at day 10, with superiority vs piracetam and pyriditol. Side effects (pulse lability, sweating, irritability, insomnia) in 11% of users. Russian-language methodology limits Western evidence assessment; head-to-head active-comparator design is methodologically meaningful.

2
Combined CO and Heat Resistance

Combined carbon monoxide and heat resistance enhancement evidence.

Clinical population described in trial publication.

Combined carbon monoxide and heat resistance enhancement evidence. Occupational stress resistance application — relevant to firefighting, military, and industrial exposure contexts.

3
WADA Monitoring Program PK Study

WADA detection methods development, prompted by 2018 monitoring program inclusion.

Clinical population described in trial publication.

WADA detection methods development, prompted by 2018 monitoring program inclusion. Reflects WADA's recognition of the documented ergogenic effects without yet formally prohibiting use. Pharmacokinetic data informing Western detection methods.

Side effects and drug interactions

Common Potential side effects

Pulse lability, irritability, insomnia, sweating reported in 11% of users (1988 trial).
Headache.
GI upset.
WADA monitoring — athletes warned, not yet prohibited but flagged.
Pregnancy/lactation: avoid.
Long-term safety: Russian/CIS clinical experience supports general safety; Western evaluation limited.
Tissue accumulation may produce sustained effects beyond treatment course.

Important Drug interactions

Nootropic drugs (piracetam): synergistic effects — used in Russian combination protocols.
Psychostimulants: synergistic enhancement.
Adaptogens (Rhodiola, Eleuthero): synergistic actoprotective effects.
Antibiotics: reduces side effects (Russian clinical use).
Immunosuppressants: theoretical reduction of side effects.
Tranquilizers (benzodiazepines): theoretical reduction of side effects.

More Energy Ingredients

Energy
Caffeine
Caffeine, a natural stimulant found in coffee, tea, and other plants, is commonly suppleme…
Energy
Iron
Iron is an essential mineral best known for its central role in making hemoglobin, the pro…
Energy
Pantothenic Acid
Pantothenic acid (vitamin B5) is an essential water-soluble vitamin needed to make coenzym…
Energy
Riboflavin
Riboflavin (vitamin B2) is an essential water-soluble vitamin central to energy production…

Explore Other Ingredients

Cognitive
L-Theanine
L-Theanine, an amino acid primarily found in green tea (Camellia sinensis), is commonly su…
Antioxidant
Milk Thistle
Milk thistle, derived from the Silybum marianum plant, contains silymarin, a compound know…
Energy
SalidroPure™ (Pure Salidroside)
SalidroPure™ is NNB Nutrition's precision-fermented pure salidroside — the primary bioacti…

Frequently asked questions about Bemethyl (Bemitil / Metaprot)

What is bemethyl?

Bemethyl (bemitil) is a compound developed in Russia as an actoprotector, studied for endurance, recovery, and resilience to physical and mental stress. It is not approved as a drug or dietary supplement in the US.

What is bemethyl used for?

In Russian research it is used to support physical and mental performance under demanding conditions, recovery, and adaptation to stress, partly by supporting protein synthesis. Western evidence is limited.

How is bemethyl used?

In Russian practice it is taken orally at prescribed doses, sometimes in cycles. Because it is unapproved outside Russia, caution is essential.

Is bemethyl safe?

Russian data suggests reasonable tolerability, but Western safety data is limited and it is not an approved supplement or drug in many countries. Anyone considering it should be cautious and consult a healthcare professional.

What is the recommended dosage of Bemethyl?

The clinically studied dose is Russian/CIS approved: 250-500 mg 1-2x/day for asthenia; courses 3-5 days with 2-3 day breaks. Athletic: 250 mg 2x/day. Always follow the product label and check with a healthcare provider for personal advice.

Is Bemethyl safe, and does it have side effects?

For most healthy adults, Bemethyl is well tolerated at studied doses. Reported effects can include: Pulse lability, irritability, insomnia, sweating reported in 11% of users (1988 trial). Headache. It may also interact with some medications. Bemethyl is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Bemethyl interact with any medications?

Possible interactions include: Nootropic drugs (piracetam): synergistic effects — used in Russian combination protocols. Psychostimulants: synergistic enhancement. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Bemethyl?

NutraSmarts rates the evidence for Bemethyl as Limited (2 out of 5). It is backed by 3 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Oliynyk S, Oh S The pharmacology of actoprotectors: practical application for improvement of mental and physical performance Biomol Ther (Seoul). 2012;20(5):446-456. doi:10.4062/biomolther.2012.20.5.446.PubMedUsed to support: Comprehensive pharmacology review of the actoprotector class with bemitil (bemethyl) as the primary prototypic agent; covers mechanisms of enhanced physical/mental performance without increased oxygen consumption, antihypoxic effects, and practical clinical applications. Supports 'Physical performance enhancement', 'Hypoxia tolerance', and the actoprotector class definition.
  2. Boĭko SS, Bobkov IuG, Neznamov GG, Serebriakova TV Pharmacokinetics and the clinical effect of bemitil after a single administration Farmakol Toksikol. 1986;49(5):17-20..PubMedUsed to support: Early clinical pharmacokinetic study of bemitil in patients with asthenic states; demonstrated that pharmacokinetic profile correlated with clinical response (psychostimulating vs. tranquilizing) in asthenic/neurotic patients. Supports 'Asthenic disorders' benefit and provides pharmacokinetic basis for dosing.
  3. Makarov VI, Tiurenkov IN, Klauchek SV, Nalivaĭko IIu, Antipova AIu The enhancement of human thermal resistance by the single use of bemitil and fenibut Eksp Klin Farmakol. 1997;60(1):68-71..PubMedUsed to support: Human study showing bemitil significantly enhanced heat tolerance as a single dose intervention; directly supports 'Heat tolerance and combined CO/heat protection' benefit.